Provided by Tiger Fintech (Singapore) Pte. Ltd.

Anebulo Pharmaceuticals, Inc.

2.28
-0.0900-3.80%
Post-market: 2.280.00000.00%16:04 EST
Volume:20.44K
Turnover:48.00K
Market Cap:93.67M
PE:-9.09
High:2.39
Open:2.33
Low:2.28
Close:2.37
52wk High:3.42
52wk Low:0.8001
Shares:41.08M
Float Shares:3.40M
Volume Ratio:1.09
T/O Rate:0.60%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2509
EPS(LYR):-0.2509
ROE:-109.69%
ROA:-71.09%
PB:8.04
PE(LYR):-9.09

Loading ...

Jul 05, 2022

Major Issues Report

8-K - Current report
May 24, 2022

Major Issues Report

8-K - Current report
May 11, 2022

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
May 11, 2022

Major Issues Report

8-K - Current report
Apr 22, 2022

Employee Stock Ownership

S-8 - Securities to be offered to employees in employee benefit plans
Apr 01, 2022

Major Issues Report

8-K - Current report
Feb 11, 2022

Major Issues Report

8-K - Current report
Feb 11, 2022

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
Jan 05, 2022

Major Issues Report

8-K - Current report
Jan 03, 2022

Major Issues Report

8-K - Current report
Dec 03, 2021

Statement Of Changes In Beneficial Ownership

4 - Statement of changes in beneficial ownership of securities
Dec 03, 2021

Statement Of Changes In Beneficial Ownership

4 - Statement of changes in beneficial ownership of securities
Jun 21, 2021

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
May 17, 2021

Beneficial Ownership Change

SC 13D - General statement of acquisition of beneficial ownership
May 05, 2021

Correspondence

CORRESP [Cover] - Correspondence
May 05, 2021

[Amend]Public Prospectus

S-1/A [Amend] - General form for registration of securities under the Securities Act of 1933
May 05, 2021

Correspondence

CORRESP [Cover] - Correspondence
May 05, 2021

Correspondence

CORRESP [Cover] - Correspondence
Apr 26, 2021

[Amend]Public Prospectus

S-1/A [Amend] - General form for registration of securities under the Securities Act of 1933
Apr 26, 2021

Correspondence

CORRESP [Cover] - Correspondence